FDA advisers to vote on approval of Grail's multi-cancer blood test

An independent panel of experts is set to vote on whether to recommend FDA approval for Grail's Galleri blood test, which claims to detect up to 50 types of cancer. This decision comes as the company seeks regulatory endorsement for its multi-cancer screening technology.

Originally published by npr